Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study
Authors
Rothwell, Dominic GAyub, Mahmood
Cook, Natalie
Thistlethwaite, Fiona C
Carter, Louise
Dean, Emma J
Smith, Nigel K
Villa, Shaun
Dransfield, Joanne
Clipson, Alexandra
White, Daniel J
Nessa, Kamrun
Ferdous, Saba
Howell, Matthew
Gupta, Avinash
Kilerci, Bedirhan
Mohan, Sumitra
Frese, Kristopher K
Gulati, Sakshi
Miller, Crispin J
Jordan, Allan M
Eaton, H
Hickson, N
O'Brien, Ciara S
Graham, Donna
Kelly, Claire
Aruketty, Sreeja
Metcalf, Robert
Chiramel, Jaseela
Tinsley, Nadina
Vickers, Alexander J
Kurup, Roopa
Frost, Hannah
Stevenson, Julie
Southam, Siobhan
Landers, Donal
Wallace, A
Marais, Richard
Hughes, Andrew M
Brady, Ged
Dive, Caroline
Krebs, Matthew G
Affiliation
Clinical Experimental Pharmacology Group, CRUK Manchester Institute, Manchester, UKClinical Experimental Pharmacology Group, CRUK Manchester Institute, Manchester, UKIssue Date
2019
Metadata
Show full item recordAbstract
Next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) supports blood-based genomic profiling but is not yet routinely implemented in the setting of a phase I trials clinic. TARGET is a molecular profiling program with the primary aim to match patients with a broad range of advanced cancers to early phase clinical trials on the basis of analysis of both somatic mutations and copy number alterations (CNA) across a 641 cancer-associated-gene panel in a single ctDNA assay. For the first 100 TARGET patients, ctDNA data showed good concordance with matched tumor and results were turned round within a clinically acceptable timeframe for Molecular Tumor Board (MTB) review. When a 2.5% variant allele frequency (VAF) threshold was applied, actionable mutations were identified in 41 of 100 patients, and 11 of these patients received a matched therapy. These data support the application of ctDNA in this early phase trial setting where broad genomic profiling of contemporaneous tumor material enhances patient stratification to novel therapies and provides a practical template for bringing routinely applied blood-based analyses to the clinic.Citation
Rothwell DG, Ayub M, Cook N, Thistlethwaite F, Carter L, Dean E, et al. Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nat Med. 2019; 25(5):738-43.Journal
Nature MedicineDOI
10.1038/s41591-019-0380-zPubMed ID
31011204Additional Links
https://dx.doi.org/10.1038/s41591-019-0380-zType
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1038/s41591-019-0380-z
Scopus Count
Collections
Related articles
- High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
- Authors: Park S, Olsen S, Ku BM, Lee MS, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Choi YL, Ahn MJ
- Issue date: 2021 Aug 15
- High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
- Authors: Li Y, Zhang F, Yuan P, Guo L, Jianming Y, He J
- Issue date: 2020 Jun
- Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing.
- Authors: Chang YS, Fang HY, Hung YC, Ke TW, Chang CM, Liu TY, Chen YC, Chao DS, Huang HY, Chang JG
- Issue date: 2018 Nov
- Targeted mutation detection in breast cancer using MammaSeq™.
- Authors: Smith NG, Gyanchandani R, Shah OS, Gurda GT, Lucas PC, Hartmaier RJ, Brufsky AM, Puhalla S, Bahreini A, Kota K, Wald AI, Nikiforov YE, Nikiforova MN, Oesterreich S, Lee AV
- Issue date: 2019 Feb 8
- Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.
- Authors: Zhang M, Qi C, Wang Z, Chen H, Zhao X, Zhang X, Zhou Y, Gao C, Bai Y, Jia S, Ji J
- Issue date: 2021 Sep